Access Bio (950130) Fundamentals 2026 — Revenue Analysis | SniperIQ
Access Bio (950130) is a US-listed Healthcare company in Medical - Specialties with a market capitalization of ₩78.8B, trading at ₩2240.00 on the KOE. This SniperIQ fundamentals page covers Access Bio's valuation, profitability (net margin -74.2%), revenue (₩31.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Access Bio's market cap?
Access Bio (950130) has a market capitalization of approximately ₩78.8B, trading at ₩2240.00 on the KOE. Market cap moves with the live share price.
What is Access Bio's P/E ratio?
Access Bio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Access Bio?
Access Bio runs a net profit margin of -74.2%, a gross margin of -32.3%, and an operating margin of -119.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Access Bio generate?
Access Bio reported revenue of ₩31.3B for fiscal year 2025, with net income of -₩82.1B and earnings per share (EPS) of -2332. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Access Bio pay a dividend?
Access Bio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Access Bio financially healthy?
Access Bio carries a debt-to-equity ratio of 0.10x and a current ratio of 15.67x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Access Bio a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Access Bio (950130) the key facts are: market cap ₩78.8B, revenue ₩31.3B, 52-week range 2085-5570. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Access Bio's full fundamentals live
Get Access Bio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.